Parabilis Medicines, Inc. is a clinical-stage biotechnology company that remains pre-revenue and has incurred significant losses since inception. As of November 9, 2026, the company had approximately 125.3 million total shares outstanding and is focused on advancing its Helicon discovery platform and lead product candidate, zolucatetide.
Parabilis Medicines reported third-quarter 2026 financial results, ending the period with $1.1 billion in cash and marketable securities. The company reached alignment with the FDA on the Phase 3 registrational trial design for zolucatetide in desmoid tumors, with initiation planned for the first half of 2027. Additionally, the company entered a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination therapies for metastatic colorectal cancer.
Term
Q3 2026
“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
“The progress across our portfolio continues to strengthen our conviction in the ability of our Helicon platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients’ lives.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President